drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous 'armored' chimeric antigen receptor T-cell therapy targeting glypican-3 (GPC3); genetically modified T cells with CD3ζ and co-stimulatory domains designed to enhance activation, persistence, and cytotoxicity against GPC3-positive hepatocellular carcinoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds glypican-3 (GPC3) on hepatocellular carcinoma cells. CAR engagement activates CD3ζ and co-stimulatory signaling, driving T-cell proliferation, cytokine release, and targeted cytotoxic killing of GPC3-positive tumor cells. The “armored” design enhances activation, persistence, and function within the immunosuppressive tumor microenvironment.
drug_name
JWATM214 (GPC3-directed CAR-T cells)
nct_id_drug_ref
NCT05926726